Scarica l'app Stockscreener
32.57
16.07%
4.3631
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$28.21
Aprire:
$29.6
Volume 24 ore:
10.51M
Relative Volume:
1.90
Capitalizzazione di mercato:
$23.26B
Reddito:
$13.31M
Utile/perdita netta:
$-1.01B
Rapporto P/E:
-27.88
EPS:
-1.1685
Flusso di cassa netto:
$-766.86M
1 W Prestazione:
+12.06%
1M Prestazione:
+12.60%
6M Prestazione:
+61.54%
1 anno Prestazione:
+196.59%
Intervallo 1D:
$29.35
$32.79
Intervallo di 1 settimana:
$27.85
$32.79
Portata 52W:
$10.59
$32.79
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
32.51 | 20.43B | 13.31M | -1.01B | -766.86M | -1.1685 |
VRTX
Vertex Pharmaceuticals Inc
|
428.76 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
643.29 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.49 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.09 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
150.71 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Bernstein | Outperform |
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
ROIV: High efficacy in refractory RA, strong cash, and major launches expected in the coming year - TradingView
Roivant Sciences (ROIV) Surges 14.8% to $32.38 - AlphaStreet
Roivant Sciences Shares Jump 14.43% to $32.28 on Strong IMVT-1402 Rheumatoid Arthritis Data - International Business Times Australia
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2026 - marketscreener.com
Roivant gains after mid-stage trial data for Immunovant’s main asset - Seeking Alpha
Roivant Sciences Q4 Earnings Call Highlights - Yahoo Finance
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Movin - Benzinga
Roivant Sciences stock hits all-time high of 30.35 USD - Investing.com
Roivant Sciences Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Roivant Sciences surprises with Q4 2026 EPS beat - Investing.com
Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV) - Yahoo Finance
Roivant Sciences : Financial Results and Business Updates for the Year Ended March 31 2026 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
ROIV: Strong clinical progress, major litigation win, and robust cash position set up multiple 2027 catalysts - TradingView
Roivant Sciences Ltd. Reports FY2025 Financial Results and Key Developments in May 2026 - Minichart
Roivant shares jump 10% on earnings beat despite revenue miss By Investing.com - Investing.com Australia
Roivant Sciences Ltd. 2026 Annual Report: Business Overview, Risk Factors, and Product Pipeline Highlights - Minichart
Roivant shares jump 10% on earnings beat despite revenue miss - Investing.com
Roivant Sciences Ltd. FY 2026: Revenue $8.26M, EPS ($0.54) — 10-K Summary - TradingView
Roivant Reports $355.7M Q4 Income from Continuing Ops, $4.3B Cash Position - TradingView
Earnings Flash (ROIV) Roivant Posts Fiscal Q4 EPS From Continuing Operations $0.28 - marketscreener.com
Roivant (ROIV) touts late-stage pipeline and Genevant’s $2.25B Moderna IP deal - Stock Titan
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q4 Revenue $2.5M, vs. FactSet Est of $3.4M - marketscreener.com
Roivant (NASDAQ: ROIV) books $770M legal gain and holds $4.3B cash - Stock Titan
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update - The Manila Times
Roivant Sciences Ltd. (ROIV) Tops Q4 EPS by 57c - StreetInsider
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.23, Implies 28% Upside - TradingView
Roivant Sciences Q4 2026 earnings preview - MSN
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why - sharewise.com
A Look At Roivant Sciences (ROIV) Valuation As IMVT-1402 And Earnings Outlook Draw Investor Focus - simplywall.st
Roivant in the spotlight as earnings loom with approval ahead - Investing.com India
Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight - GlobeNewswire Inc.
Book value per share of Roivant Sciences Ltd. – LSX:A3C4MS - TradingView
Roivant Sciences Q4 2026 Earnings Preview — May 20, Street Expects -$0.35 EPS - AlphaStreet
Trading the Move, Not the Narrative: (ROIV) Edition - Stock Traders Daily
Earnings Preview: ROIV to Report Financial Results Pre-market on May 20 - Moomoo
ROIVANT SCIENCES LTD (NASDAQ:ROIV) Flashes Strong Breakout Setup with Near-Perfect Technical and Setup Quality Ratings - ChartMill
TradingKey - TradingKey
ROIV Q4'25 Earnings: revenue estimate is 3.41M USD - TradingView
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a 24.88% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
ROIV Stock Price, Quote & Chart | ROIVANT SCIENCES LTD (NASDAQ:ROIV) - ChartMill
Insiders At Roivant Sciences Sold US$112m In Stock, Alluding To Potential Weakness - Moomoo
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
A Look At Roivant Sciences (ROIV) Valuation After Encouraging Phase 2 Brepocitinib Data - Yahoo Finance
Baron Fund Puts Spotlight On Roivant’s Brepocitinib And Valuation Gap - simplywall.st
Assessing Roivant Sciences (ROIV) Valuation After Strong 1-Year Return And Recent Share Price Momentum - simplywall.st
Who is Vivek Ramaswamy, 2026 Republican nominee for Ohio governor? - marketscreener.com
MSN Money - MSN
Baron Health Care Fund Reports Roivant Sciences as Top Q1 2026 Performer - HarianBasis.co
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Roivant Sciences Ltd Azioni (ROIV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Apr 20 '26 |
Sale |
29.59 |
200,000 |
5,918,000 |
1,647,546 |
| Gline Matthew | CEO |
Apr 16 '26 |
Sale |
29.16 |
289,774 |
8,449,810 |
16,736,116 |
0.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):